In December 2024, Pieris Pharmaceuticals merged with Palvella Therapeutics, Inc. Palvella Therapeutics (Nasdaq: PVLA), is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. For more information about the Company and updates, please visit www.palvellatx.com or follow us on LinkedIn.
Recent Event
2024 Annual Meeting of Stockholders
Sign Up for Email Alerts
Receive updates straight into your inbox
Investor Contact Information
Company
Pieris Pharmaceuticals, Inc.
225 Franklin St., Floor 26
Boston, MA 02110
USA
T: +1-857-246-8998
info@pieris.com
Transfer Agent
Computershare
P.O. Box 43006
Providence RI 02940-3078
T: 1-877-373-6374 (US, Canada, Puerto Rico) or 1-781-575-3100 (non-US)
web.queries@computershare.com
www.computershare.com/investor
Courier Delivery
150 Royall St.
Suite 101
Canton, MA 02021